Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer

Inclusion Criteria

• •Patients must have pathological diagnosis of renal cell carcinoma that is metastatic or surgically unresectable; the histology must be clear cell carcinoma or predominant clear cell carcinoma
• •Patients may have received up to two prior therapies including vascular endothelial growth factor (VEGF), mammalian target of rapamycin (mTOR) and programmed cell death (PD)-1/PD ligand 1 (L1) inhibitors; prior palliative radiation to metastatic lesion(s) is permitted, provided there is at least one measurable and/or evaluable lesion(s) that has not been irradiated
• •Patients must have measurable or evaluable disease
• •Eastern Cooperative Oncology Group (ECOG) performance status 0
• •Life expectancy of greater than 6 months
• •Hemoglobin \>= 12 g/dL
• •Leukocytes \>= 3,000/mm\^3
• •Absolute neutrophil count \>= 1,500/mm\^3
• •Platelets \>= 100,000/mm\^3
• •Total bilirubin =\< 1.5 x laboratory upper limit of normal
• •Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 2.5 x laboratory upper limit of normal
• •Creatinine =\< 1.5 x laboratory upper limit of normal or calculated creatinine clearance of \>= 50 ml/min
• •Lactate dehydrogenase (LDH) within normal limits (WNL)
• •Corrected calcium =\< 10 mg/dL
• •Prothrombin time (PT)/international normalized ratio (INR) =\< 1.5
• •Urine protein \< 1+; if \>= 1+, 24 hour urine protein should be obtained and should be \< 1000 mg
• •Forced expiratory volume in 1 second (FEV1) \>= 2.0 liters or \>= 75% of predicted for height and age; (pulmonary function tests \[PFTs\] are required for patients over 50 or with significant pulmonary or smoking history)
• •No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina; patients who are over 40 or have had previous myocardial infarction greater than 6 months prior to entry will be required to have a negative or low probability cardiac stress test for cardiac ischemia
• •No history of cerebrovascular accident or transient ischemic attacks
• •The effects of entinostat on the developing human fetus at the recommended therapeutic dose are unknown; for this reason Women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; men with female partners of child bearing potential must also agree to use adequate contraception
• •Ability to understand and the willingness to sign a written informed consent document